These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 30219772)

  • 1. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
    Smolen JS; Genovese MC; Takeuchi T; Hyslop DL; Macias WL; Rooney T; Chen L; Dickson CL; Riddle Camp J; Cardillo TE; Ishii T; Winthrop KL
    J Rheumatol; 2019 Jan; 46(1):7-18. PubMed ID: 30219772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
    Harigai M; Takeuchi T; Smolen JS; Winthrop KL; Nishikawa A; Rooney TP; Saifan CG; Issa M; Isaka Y; Akashi N; Ishii T; Tanaka Y
    Mod Rheumatol; 2020 Jan; 30(1):36-43. PubMed ID: 30784354
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
    Winthrop KL; Harigai M; Genovese MC; Lindsey S; Takeuchi T; Fleischmann R; Bradley JD; Byers NL; Hyslop DL; Issa M; Nishikawa A; Rooney TP; Witt S; Dickson CL; Smolen JS; Dougados M
    Ann Rheum Dis; 2020 Oct; 79(10):1290-1297. PubMed ID: 32788396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
    Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
    J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
    N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
    Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.
    Keystone EC; Genovese MC; Schlichting DE; de la Torre I; Beattie SD; Rooney TP; Taylor PC
    J Rheumatol; 2018 Jan; 45(1):14-21. PubMed ID: 28811354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
    Taylor PC; Weinblatt ME; Burmester GR; Rooney TP; Witt S; Walls CD; Issa M; Salinas CA; Saifan C; Zhang X; Cardoso A; González-Gay MA; Takeuchi T
    Arthritis Rheumatol; 2019 Jul; 71(7):1042-1055. PubMed ID: 30663869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
    Keystone EC; Taylor PC; Drescher E; Schlichting DE; Beattie SD; Berclaz PY; Lee CH; Fidelus-Gort RK; Luchi ME; Rooney TP; Macias WL; Genovese MC
    Ann Rheum Dis; 2015 Feb; 74(2):333-40. PubMed ID: 25431052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.
    Tanaka Y; Ishii T; Cai Z; Schlichting D; Rooney T; Macias W
    Mod Rheumatol; 2018 Jan; 28(1):20-29. PubMed ID: 28440680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
    Taylor PC; Kremer JM; Emery P; Zuckerman SH; Ruotolo G; Zhong J; Chen L; Witt S; Saifan C; Kurzawa M; Otvos JD; Connelly MA; Macias WL; Schlichting DE; Rooney TP; de Bono S; McInnes IB
    Ann Rheum Dis; 2018 Jul; 77(7):988-995. PubMed ID: 29463520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
    Dougados M; van der Heijde D; Chen YC; Greenwald M; Drescher E; Liu J; Beattie S; Witt S; de la Torre I; Gaich C; Rooney T; Schlichting D; de Bono S; Emery P
    Ann Rheum Dis; 2017 Jan; 76(1):88-95. PubMed ID: 27689735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials.
    Chen YC; Yoo DH; Lee CK; Li KJ; Won JE; Wu WS; Zhong J; Nicolay C; Walls CD; Tanaka Y
    Int J Rheum Dis; 2020 Jan; 23(1):65-73. PubMed ID: 31729189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
    Tanaka Y; Atsumi T; Amano K; Harigai M; Ishii T; Kawaguchi O; Rooney TP; Akashi N; Takeuchi T
    Mod Rheumatol; 2018 Jul; 28(4):583-591. PubMed ID: 29134891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
    Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS
    N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis.
    Genovese MC; Smolen JS; Takeuchi T; Burmester G; Brinker D; Rooney TP; Zhong J; Daojun M; Saifan C; Cardoso A; Issa M; Wu WS; Winthrop KL
    Lancet Rheumatol; 2020 Jun; 2(6):e347-e357. PubMed ID: 38273598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
    Tanaka Y; Fautrel B; Keystone EC; Ortmann RA; Xie L; Zhu B; Issa M; Patel H; Gaich CL; de Bono S; Rooney TP; Taylor PC
    Ann Rheum Dis; 2019 Jul; 78(7):890-898. PubMed ID: 31040122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
    Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
    Fleischmann R; Schiff M; van der Heijde D; Ramos-Remus C; Spindler A; Stanislav M; Zerbini CA; Gurbuz S; Dickson C; de Bono S; Schlichting D; Beattie S; Kuo WL; Rooney T; Macias W; Takeuchi T
    Arthritis Rheumatol; 2017 Mar; 69(3):506-517. PubMed ID: 27723271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.